论文部分内容阅读
随着异基因造血干细胞移植(allo-HSCT)在血液系统恶性肿瘤治疗中的广泛应用,移植相关并发症的防治日益受到重视。出血性膀胱炎(hemor-rhagic cystitis,HC)是移植后常见并发症之一,根据移植类型其发生率从10%到60%不等,其中重度HC的发生率约为4%~6%[1]。目前,重度HC临床上尚无明
With the widespread use of allogeneic hematopoietic stem cell transplantation (hematopoietic stem cell transplantation) in the treatment of hematological malignancies, prevention and treatment of transplant-related complications are increasingly valued. Hemor-rhagic cystitis (HC) is one of the common complication after transplantation. The incidence of HC is about 4% -6% depending on the type of transplant. The incidence of severe HC varies from 10% to 60% [ 1]. At present, severe HC is still clinically unknown